FDA 승인

추적 기업의 최근 FDA 승인 59건. 글로벌 메이저는 최근 4년, 국내사는 전체. 출처: openFDA

• 2026-06-17GSK글로벌UTEBZI · tebipenem pivoxil hydrobromideFDA ↗
• 2026-03-17얀센(J&J)글로벌ICOTYDE · icotrokinra hydrochlorideFDA ↗
• 2026-02-13얀센(J&J)글로벌RYBREVANT FASPRO · amivantamab and hyaluronidase-lpujFDA ↗
• 2025-12-17얀센(J&J)글로벌RYBREVANT FASPRO · amivantamab and hyaluronidase-lpujFDA ↗
• 2025-09-30노바티스글로벌RHAPSIDO · remibrutinibFDA ↗
• 2025-09-19머크(MSD)글로벌KEYTRUDA QLEX · pembrolizumabFDA ↗
• 2025-09-10아스트라제네카글로벌KOSELUGO · selumetinibFDA ↗
• 2025-09-09얀센(J&J)글로벌INLEXZO · gemcitabine hydrochlorideFDA ↗
• 2025-06-09머크(MSD)글로벌ENFLONSIA · clesrovimab-cforFDA ↗
• 2025-04-29얀센(J&J)글로벌IMAAVY · nipocalimab-aahuFDA ↗
• 2025-04-02노바티스글로벌VANRAFIA · atrasentan hydrochlorideFDA ↗
• 2025-03-25GSK글로벌BLUJEPA · gepotidacin mesylateFDA ↗
• 2025-02-13삼성바이오에피스DENOSUMAB-DSSB · denosumab-dssbFDA ↗
• 2025-02-07애브비글로벌EMBLAVEO · avibactam sodiumFDA ↗
• 2024-12-27BMS글로벌OPDIVO QVANTIG · nivolumabFDA ↗
• 2024-12-27BMS글로벌OPDIVO QVANTIG · nivolumabFDA ↗
• 2024-10-16애브비글로벌VYALEV · foscarbidopaFDA ↗
• 2024-08-19얀센(J&J)글로벌LAZCLUZE · lazertinib mesylateFDA ↗
• 2024-07-19삼성바이오에피스EPYSQLI · eculizumab-aaghFDA ↗
• 2024-06-28삼성바이오에피스PYZCHIVA · ustekinumab-ttweFDA ↗
• 2024-06-28삼성바이오에피스PYZCHIVA · ustekinumab-ttweFDA ↗
• 2024-05-20삼성바이오에피스OPUVIZ · aflibercept-yszyFDA ↗
• 2024-04-26애브비글로벌RINVOQ LQ · upadacitinibFDA ↗
• 2024-04-24노바티스글로벌VIJOICE · alpelisibFDA ↗
• 2024-04-12노바티스글로벌ENTRESTO SPRINKLE · sacubitrilFDA ↗
• 2024-03-26머크(MSD)글로벌WINREVAIR · sotatercept-csrkFDA ↗
• 2024-03-07화이자글로벌TALZENNA · talazoparib tosylateFDA ↗
• 2023-12-05노바티스글로벌FABHALTA · iptacopan hydrochlorideFDA ↗
• 2023-11-16아스트라제네카글로벌TRUQAP · capivasertibFDA ↗
• 2023-10-20셀트리온ZYMFENTRA · infliximab-dyybFDA ↗
• 2023-10-12화이자글로벌VELSIPITY · etrasimod arginineFDA ↗
• 2023-09-15GSK글로벌OJJAARA · momelotinib dihydrochlorideFDA ↗
• 2023-08-18리제네론글로벌EYLEA HD · afliberceptFDA ↗
• 2023-08-18리제네론글로벌VEOPOZ · pozelimab-bbfgFDA ↗
• 2023-08-11얀센(J&J)글로벌AKEEGA · abiraterone acetateFDA ↗
• 2023-08-09얀센(J&J)글로벌TALVEY · talquetamab-tgvsFDA ↗
• 2023-06-23화이자글로벌LITFULO · ritlecitinib tosylateFDA ↗
• 2023-05-25화이자글로벌PAXLOVID (COPACKAGED) · nirmatrelvirFDA ↗
• 2023-05-23셀트리온YUFLYMA · adalimumab-aatyFDA ↗
• 2023-04-28아스트라제네카글로벌SYMBICORT AEROSPHERE · budesonideFDA ↗
• 2023-04-26GSK글로벌ZEJULA · niraparib tosylateFDA ↗
• 2023-03-16노바티스글로벌TAFINLAR · dabrafenib mesylateFDA ↗
• 2023-03-16노바티스글로벌MEKINIST · trametinibFDA ↗
• 2023-03-09화이자글로벌ZAVZPRET · zavegepant hydrochlorideFDA ↗
• 2023-02-01GSK글로벌JESDUVROQ · daprodustatFDA ↗
• 2023-01-10아스트라제네카글로벌AIRSUPRA · albuterol sulfateFDA ↗
• 2022-10-25얀센(J&J)글로벌TECVAYLI · teclistamab-cqyvFDA ↗
• 2022-09-27셀트리온VEGZELMA · bevacizumab-adcdFDA ↗
• 2022-08-03아스트라제네카글로벌CALQUENCE · acalabrutinib maleateFDA ↗
• 2022-04-05노바티스글로벌VIJOICE · alpelisibFDA ↗
• 2022-03-23노바티스글로벌LOCAMETZ · gallium ga-68 gozetotideFDA ↗
• 2022-03-23노바티스글로벌PLUVICTO · lutetium lu-177 vipivotide tetraxetanFDA ↗
• 2022-01-14화이자글로벌CIBINQO · abrocitinibFDA ↗
• 2021-09-17삼성바이오에피스BYOOVIZ · ranibizumab-nunaFDA ↗
• 2019-11-21SK바이오팜XCOPRI · cenobamateFDA ↗
• 2019-07-23삼성바이오에피스HADLIMA · adalimumab-bwwdFDA ↗
• 2019-04-25삼성바이오에피스ETICOVO · etanercept-ykroFDA ↗
• 2019-01-18삼성바이오에피스ONTRUZANT · trastuzumab-dttbFDA ↗
• 2017-04-21삼성바이오에피스RENFLEXIS · infliximab-abdaFDA ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.